Literature DB >> 11187915

Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991.

W A Kamps1, A J Veerman, E R van Wering, J F van Weerden, R Slater, A van der Does-van den Berg.   

Abstract

Here we report the long-term results of the DCLSG protocols ALL-6 and -7 with special emphasis on the incidence of CNS relapse after treatment without cranial irradiation. In DCLSG protocol ALL-6 (1984-1988), designed for patients with ALL non-high risk (ALL-NHR) (WBC <50 x 10(9)/l, no mediastinal mass, no B cell phenotype and no CNS involvement at diagnosis, comprising 71% of all ALL patients), CNS prophylaxis consisted of a combination of three methods of chemotherapeutic CNS prophylaxis (the use of dexamethasone during induction and maintenance therapy, i.v. medium dose methotrexate and prolonged administration of intrathecal triple therapy). Total duration of treatment: 116 weeks. 190 patients were enrolled in the study. At 10 years, the EFS rate for all patients is 81.5 +/- 2.8%, the survival rate 84.8 +/- 2.7%, and the cumulative incidence of isolated CNS relapse 1.1 +/- 0.8%. The 10-year survival rate for the 139/190 (73.1%) patients with standard risk non-T lineage ALL according to the NCI risk criteria is 80.5 +/- 3.4%. DCLSG protocol-7 was identical to the intensive ALL-BFM-86 protocol, but cranial irradiation was restricted to patients with initial CNS involvement. Patients were stratified into three risk groups (SRG, RG and EG). Treatment duration was 18 months. 218 patients were enrolled in the study. At 10 years, the EFS rate for all patients is 63.4 +/- 3.3%, the survival rate 76.4 +/- 3.0%, the 5-year cumulative incidence of isolated CNS relapse 5.7 +/- 1.8%. The EFS rate at 10 years of the 127/218 (58.3%) patients with standard risk non-T-lineage ALL according to the NCI risk criteria was 67.9 +/- 4.3%, which is not significantly different from the results achieved in this category of patients with the moderately intensive treatment according to protocol ALL-6 (logrank P = 0.17). These DCLSG studies indicate that omission of cranial irradiation does not jeopardize the overall good results.

Entities:  

Mesh:

Year:  2000        PMID: 11187915     DOI: 10.1038/sj.leu.2401964

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

Review 1.  International collaboration on childhood leukemia.

Authors:  Ching-Hon Pui; Raul C Ribeiro
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Feasibility of neuropsychological assessment in leukaemia patients shortly after diagnosis: directions for future prospective research.

Authors:  N C Jansen; A Kingma; P Tellegen; R I van Dommelen; A Bouma; A Veerman; W A Kamps
Journal:  Arch Dis Child       Date:  2005-03       Impact factor: 3.791

3.  Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children's Cancer Group.

Authors:  Yong Zhuang; Kefei Wu; Xiaofan Zhu; Jiaoyang Cai; Shaoyan Hu; Ju Gao; Hua Jiang; Xiaowen Zhai; Xin Tian; Yongjun Fang; Runming Jin; Qun Hu; Hui Jiang; Ningling Wang; Lirong Sun; Wing Kwan Leung; Minghua Yang; Kaili Pan; Xuedong Wu; Changda Liang; Shuhong Shen; Jie Yu; Xiuli Ju
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 4.  Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.

Authors:  Nobuko Hijiya; Kirsten K Ness; Raul C Ribeiro; Melissa M Hudson
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

5.  Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998.

Authors:  Isabel Badell; Arturo Muñoz; Jesús Estella; Rafael Fernández-Delgado; Germán Javier; Amparo Verdeguer; Josep Cubells
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

6.  Early Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in Yogyakarta.

Authors:  Pudjo H Widjajanto; Sutaryo Sutaryo; Ignatius Purwanto; Peter M Vd Ven; Anjo J P Veerman
Journal:  J Oncol       Date:  2012-04-03       Impact factor: 4.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.